TWI562989B - Uracil derivatives as axl and c-met kinase inhibitors - Google Patents
Uracil derivatives as axl and c-met kinase inhibitorsInfo
- Publication number
- TWI562989B TWI562989B TW101142365A TW101142365A TWI562989B TW I562989 B TWI562989 B TW I562989B TW 101142365 A TW101142365 A TW 101142365A TW 101142365 A TW101142365 A TW 101142365A TW I562989 B TWI562989 B TW I562989B
- Authority
- TW
- Taiwan
- Prior art keywords
- axl
- kinase inhibitors
- met kinase
- uracil derivatives
- uracil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161559312P | 2011-11-14 | 2011-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201332992A TW201332992A (en) | 2013-08-16 |
TWI562989B true TWI562989B (en) | 2016-12-21 |
Family
ID=47297443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW101142365A TWI562989B (en) | 2011-11-14 | 2012-11-14 | Uracil derivatives as axl and c-met kinase inhibitors |
Country Status (26)
Country | Link |
---|---|
US (5) | US9029538B2 (en) |
EP (2) | EP2780338B1 (en) |
JP (2) | JP6051434B2 (en) |
KR (1) | KR20140090678A (en) |
CN (2) | CN103958497B (en) |
AR (1) | AR088872A1 (en) |
AU (2) | AU2012339640B2 (en) |
BR (1) | BR112014011548A2 (en) |
CA (1) | CA2852697A1 (en) |
DK (1) | DK2780338T3 (en) |
EA (1) | EA023521B1 (en) |
ES (1) | ES2614824T3 (en) |
HK (1) | HK1202528A1 (en) |
HU (1) | HUE033032T2 (en) |
IL (3) | IL232405A (en) |
MX (1) | MX342241B (en) |
PH (1) | PH12016501535A1 (en) |
PL (1) | PL2780338T3 (en) |
PT (1) | PT2780338T (en) |
SG (2) | SG10201510307WA (en) |
SI (1) | SI2780338T1 (en) |
TW (1) | TWI562989B (en) |
UA (1) | UA114900C2 (en) |
UY (1) | UY34451A (en) |
WO (1) | WO2013074633A1 (en) |
ZA (1) | ZA201402940B (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR088872A1 (en) | 2011-11-14 | 2014-07-16 | Cephalon Inc | URACILO DERIVATIVES AS INHIBITORS OF THE AXL AND C-MET KINASE |
CN102643268B (en) * | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | Quinoline and cinnoline compound and application thereof |
BR102013027577A2 (en) * | 2012-10-25 | 2016-03-29 | Memorialsloan Kettering Cancer Ct | method of detecting an increased axl or gas6 level and method of identifying an egfr inhibitor resistant cancer patient |
JP6423873B2 (en) | 2013-07-08 | 2018-11-14 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 6-membered C-N-linked aryl sulfide derivatives and aryl sulfoxide derivatives as pest control agents |
TWI649308B (en) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | Quinoline derivative |
JP2016527274A (en) * | 2013-08-02 | 2016-09-08 | イグナイタ インコーポレイテッド | Methods for treating various cancers using AXL / cMET inhibitors alone or in combination with other drugs |
EP3066098A1 (en) * | 2013-11-08 | 2016-09-14 | Bayer Pharma Aktiengesellschaft | Substituted uracils and use thereof |
CN105873919A (en) | 2013-11-08 | 2016-08-17 | 拜耳医药股份有限公司 | Substituted uracils as chymase inhibitors |
EP3071204B1 (en) * | 2013-11-20 | 2019-02-20 | SignalChem Lifesciences Corp. | Quinazoline derivatives as tam family kinase inhibitors |
JP6496731B2 (en) | 2013-11-27 | 2019-04-03 | シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation | Aminopyridine derivatives as TAM family kinase inhibitors |
SG11201605207PA (en) * | 2013-12-26 | 2016-07-28 | Ignyta Inc | Pyrazolo[1,5-a]pyridine derivatives and methods of their use |
ES2749726T3 (en) | 2014-12-25 | 2020-03-23 | Ono Pharmaceutical Co | Quinoline derivative |
CN112028825A (en) * | 2015-04-07 | 2020-12-04 | 广东众生睿创生物科技有限公司 | Tyrosine kinase inhibitor and pharmaceutical composition containing same |
KR102499359B1 (en) | 2015-04-14 | 2023-02-10 | 주식회사 큐리언트 | Quinoline derivatives as TAM RTK inhibitors |
US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
CN106467541B (en) * | 2015-08-18 | 2019-04-05 | 暨南大学 | Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application |
WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
KR20180086187A (en) | 2015-10-05 | 2018-07-30 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | Clearance of protein aggregates including phospholipase D and tau, and treatment of protein diseases |
EP3421039B1 (en) | 2016-02-26 | 2021-10-06 | ONO Pharmaceutical Co., Ltd. | Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor |
KR20230111268A (en) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Pyrrolotriazine compounds as tam inhibitors |
JP2019527231A (en) * | 2016-08-01 | 2019-09-26 | イグナイタ インコーポレイテッド | Combinations for treating cancer |
WO2018026877A1 (en) | 2016-08-05 | 2018-02-08 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
CN109715157A (en) * | 2016-08-24 | 2019-05-03 | 亚尼塔公司 | Combination for treating cancer |
CN106543145B (en) * | 2016-10-28 | 2019-07-19 | 山西医科大学 | C-Met kinases presses down agent 3- (4- fluorophenyl) pyrimidone -5- benzoic acid amides derivative, preparation method and application |
CN108250200A (en) * | 2016-12-28 | 2018-07-06 | 中国科学院上海药物研究所 | A kind of compound and its preparation and application with Axl inhibitory activity |
RU2019123279A (en) | 2017-01-26 | 2021-02-26 | Оно Фармасьютикал Ко., Лтд. | ETHANE-SULFONATE SALT OF QUINOLINE DERIVATIVE |
CN108623568B (en) * | 2017-03-21 | 2022-04-19 | 南京汇诚制药有限公司 | Salt form of 9,10 dihydrophenanthrene hepatitis C virus inhibitor and preparation thereof |
EP3673907A4 (en) | 2017-08-23 | 2020-08-19 | ONO Pharmaceutical Co., Ltd. | Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component |
MD3687996T2 (en) | 2017-09-27 | 2022-04-30 | Incyte Corp | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
EP3695839A4 (en) | 2017-10-13 | 2021-07-14 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient |
CN107573340B (en) * | 2017-10-23 | 2020-11-24 | 江西科技师范大学 | Preparation and application of 2-carbamoyl-4-aryl hetero pyridine compound |
WO2019101178A1 (en) * | 2017-11-24 | 2019-05-31 | 南京明德新药研发股份有限公司 | Uracil compound as c-met/axl inhibitor |
WO2019141202A1 (en) * | 2018-01-17 | 2019-07-25 | 南京药捷安康生物科技有限公司 | Tam family kinase /and csf1r kinase inhibitor and use thereof |
WO2019213340A1 (en) * | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
CN110511218A (en) * | 2018-05-21 | 2019-11-29 | 中国科学院上海药物研究所 | A kind of and ring pyrazolone Carbox amide and preparation method thereof, pharmaceutical composition and purposes |
US10851093B2 (en) * | 2018-06-01 | 2020-12-01 | Rigel Pharmaceuticals, Inc. | Tyrosine kinase inhibitors |
AR117600A1 (en) | 2018-06-29 | 2021-08-18 | Incyte Corp | FORMULATIONS OF AN AXL / MER INHIBITOR |
WO2020038460A1 (en) * | 2018-08-24 | 2020-02-27 | 南京药捷安康生物科技有限公司 | Novel quinoline derivative inhibitor |
KR20210066820A (en) * | 2018-08-27 | 2021-06-07 | 베이징 위에즈캉타이 바이오메디슨스 컴퍼니, 리미티드 | Multi-substituted pyridone derivatives and medical uses thereof |
UY38349A (en) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES |
TW202027748A (en) * | 2018-10-12 | 2020-08-01 | 美商拓臻股份有限公司 | Thyroid hormone receptor beta agonist compounds |
CN111196814B (en) * | 2018-11-19 | 2022-12-06 | 北京赛特明强医药科技有限公司 | Aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof |
CN111320609A (en) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | THR β receptor agonist compound and preparation method and application thereof |
CN114364798A (en) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer |
CN111840299A (en) * | 2019-04-30 | 2020-10-30 | 武汉盛云生物医药科技有限责任公司 | Application of quinoline compound in preparation of cancer treatment drug |
CN111886228B (en) * | 2019-05-24 | 2024-02-23 | 南京明德新药研发有限公司 | Crystal form of c-MET/AXL inhibitor |
WO2020238802A1 (en) * | 2019-05-24 | 2020-12-03 | 南京明德新药研发有限公司 | Crystal form of c-met/axl inhibitor |
US20220324869A1 (en) * | 2019-09-06 | 2022-10-13 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Compound having axl and c-met kinase inhibitory activity, preparation thereof and application thereof |
CN112625026B (en) * | 2019-09-24 | 2022-09-09 | 药捷安康(南京)科技股份有限公司 | Quinoline derivatives of TAM family kinase inhibitors |
JP2022551422A (en) * | 2019-09-26 | 2022-12-09 | エグゼリクシス, インコーポレイテッド | Pyridone compounds and methods of use in modulating protein kinases |
US11866429B2 (en) | 2019-10-16 | 2024-01-09 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
WO2021076691A1 (en) | 2019-10-16 | 2021-04-22 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
CN113620873B (en) * | 2020-05-07 | 2023-12-08 | 沈阳药科大学 | Preparation method and application of zinc-containing binding group and quinoline skeleton compound |
CA3187605A1 (en) * | 2020-06-23 | 2021-12-30 | Chemocentryx, Inc. | Methods of treating cancer using heteroaryl-biphenyl amide derivatives |
AU2021339579A1 (en) * | 2020-09-08 | 2023-05-18 | Ideaya Biosciences Inc. | Pharmaceutical combination and tumor treatment |
CN112675170B (en) * | 2021-02-03 | 2022-02-01 | 南华大学附属第一医院 | Application of V027-0576 in preparation of antitumor drugs |
WO2022178205A1 (en) * | 2021-02-19 | 2022-08-25 | Exelixis, Inc. | Pyridone compounds and methods of use |
TW202304908A (en) * | 2021-04-14 | 2023-02-01 | 日商衛材R&D企管股份有限公司 | Tetrahydropyridopyrimidine compound |
CN117412953A (en) * | 2021-05-12 | 2024-01-16 | 微境生物医药科技(上海)有限公司 | Axl inhibitors |
JPWO2023286719A1 (en) * | 2021-07-13 | 2023-01-19 | ||
IT202100022682A1 (en) * | 2021-09-01 | 2023-03-01 | Luigi Frati | PYRIMIDINES DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS |
CN116693452A (en) * | 2023-05-24 | 2023-09-05 | 中山大学 | Quinoline derivative and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200906834A (en) * | 2007-04-13 | 2009-02-16 | Supergen Inc | Axl kinase inhibitors |
TW201006829A (en) * | 2008-05-05 | 2010-02-16 | Smithkline Beecham Corp | Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor |
CN102131783A (en) * | 2008-04-16 | 2011-07-20 | 马克斯普朗克科学发展组织 | Quinoline derivatives as axl kinase inhibitors |
WO2012028332A1 (en) * | 2010-08-28 | 2012-03-08 | Lead Discovery Center Gmbh | Pharmaceutically active compounds as axl inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143764A (en) | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
CA2263479A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Quinoline derivatives inhibiting the effect of growth factors such as vegf |
DE60033857T2 (en) | 1999-01-22 | 2007-10-25 | Kirin Beer K.K. | Derivatives of the N - ((quinolinyl) oxy) phenyl) urea and the N - ((quinazolinyl) oxy) -phenyl) urea with antitumor activity |
US7732613B2 (en) * | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2008035209A2 (en) * | 2006-05-30 | 2008-03-27 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
EP2032538A2 (en) | 2006-06-08 | 2009-03-11 | Array Biopharma, Inc. | Quinoline compounds and methods of use |
PL2268623T3 (en) | 2008-03-17 | 2015-10-30 | Ambit Biosciences Corp | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
EP2311809A1 (en) | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
SG10201602569RA (en) | 2011-04-01 | 2016-05-30 | Curis Inc | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
AR088872A1 (en) | 2011-11-14 | 2014-07-16 | Cephalon Inc | URACILO DERIVATIVES AS INHIBITORS OF THE AXL AND C-MET KINASE |
-
2012
- 2012-11-14 AR ARP120104293A patent/AR088872A1/en unknown
- 2012-11-14 UY UY0001034451A patent/UY34451A/en not_active Application Discontinuation
- 2012-11-14 ES ES12798087.8T patent/ES2614824T3/en active Active
- 2012-11-14 SI SI201230843A patent/SI2780338T1/en unknown
- 2012-11-14 KR KR1020147015807A patent/KR20140090678A/en not_active Application Discontinuation
- 2012-11-14 SG SG10201510307WA patent/SG10201510307WA/en unknown
- 2012-11-14 HU HUE12798087A patent/HUE033032T2/en unknown
- 2012-11-14 CN CN201280055840.7A patent/CN103958497B/en not_active Expired - Fee Related
- 2012-11-14 SG SG11201402004YA patent/SG11201402004YA/en unknown
- 2012-11-14 CA CA2852697A patent/CA2852697A1/en not_active Abandoned
- 2012-11-14 EP EP12798087.8A patent/EP2780338B1/en active Active
- 2012-11-14 DK DK12798087.8T patent/DK2780338T3/en active
- 2012-11-14 WO PCT/US2012/065019 patent/WO2013074633A1/en active Application Filing
- 2012-11-14 MX MX2014005766A patent/MX342241B/en active IP Right Grant
- 2012-11-14 CN CN201710670188.4A patent/CN108047201A/en active Pending
- 2012-11-14 TW TW101142365A patent/TWI562989B/en not_active IP Right Cessation
- 2012-11-14 BR BR112014011548A patent/BR112014011548A2/en not_active Application Discontinuation
- 2012-11-14 PT PT127980878T patent/PT2780338T/en unknown
- 2012-11-14 PL PL12798087T patent/PL2780338T3/en unknown
- 2012-11-14 AU AU2012339640A patent/AU2012339640B2/en not_active Ceased
- 2012-11-14 UA UAA201406453A patent/UA114900C2/en unknown
- 2012-11-14 JP JP2014541416A patent/JP6051434B2/en not_active Expired - Fee Related
- 2012-11-14 EA EA201490971A patent/EA023521B1/en not_active IP Right Cessation
- 2012-11-14 EP EP16153088.6A patent/EP3045453A1/en not_active Withdrawn
-
2014
- 2014-04-23 ZA ZA2014/02940A patent/ZA201402940B/en unknown
- 2014-05-01 IL IL232405A patent/IL232405A/en not_active IP Right Cessation
- 2014-05-13 US US14/276,138 patent/US9029538B2/en not_active Expired - Fee Related
-
2015
- 2015-03-20 HK HK15102863.3A patent/HK1202528A1/en not_active IP Right Cessation
- 2015-04-08 US US14/681,974 patent/US9522902B2/en not_active Expired - Fee Related
- 2015-04-08 US US14/681,981 patent/US9120778B2/en not_active Expired - Fee Related
-
2016
- 2016-05-16 IL IL245658A patent/IL245658A/en not_active IP Right Cessation
- 2016-08-04 PH PH12016501535A patent/PH12016501535A1/en unknown
- 2016-11-04 JP JP2016215753A patent/JP6404299B2/en not_active Expired - Fee Related
- 2016-11-08 US US15/346,582 patent/US9745283B2/en not_active Expired - Fee Related
-
2017
- 2017-02-16 AU AU2017201042A patent/AU2017201042A1/en not_active Abandoned
- 2017-05-25 IL IL252517A patent/IL252517A0/en unknown
- 2017-07-13 US US15/649,526 patent/US10017496B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200906834A (en) * | 2007-04-13 | 2009-02-16 | Supergen Inc | Axl kinase inhibitors |
CN102131783A (en) * | 2008-04-16 | 2011-07-20 | 马克斯普朗克科学发展组织 | Quinoline derivatives as axl kinase inhibitors |
TW201006829A (en) * | 2008-05-05 | 2010-02-16 | Smithkline Beecham Corp | Method of treating cancer using a cMET and AXL inhibitor and an erbB inhibitor |
WO2012028332A1 (en) * | 2010-08-28 | 2012-03-08 | Lead Discovery Center Gmbh | Pharmaceutically active compounds as axl inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL252517A0 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
HRP20181429T8 (en) | Novel benzimidazole derivatives as kinase inhibitors | |
HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
SG11201600062RA (en) | Pyrimidine derivatives as kinase inhibitors | |
ZA201406078B (en) | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors | |
HK1199880A1 (en) | Benzonitrile derivatives as kinase inhibitors | |
HK1211027A1 (en) | Pyrrolotriazinone derivatives as pi3k inhibitors pi3k | |
HK1210777A1 (en) | Quinazolinone derivatives as parp inhibitors parp | |
IL232234A0 (en) | Aminopyrimidine kinase inhibitors | |
IL228928A0 (en) | Aminopyrimidine kinase inhibitors | |
SG11201500973WA (en) | Amino-quinolines as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |